Treats major depressive disorder. ANDA 90555, held by Aurobindo Pharma. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 90555 (Venlafaxine Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Apr 7, 2010, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 7, 2010 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 25MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 50MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 100MG BASE · tablet;oral | Venlafaxine Hydrochloride | Rx |
| Aug 18, 2023 | Supplement 24Labeling · Standard review | Approved | None posted |
| Sep 20, 2021 | Supplement 19Labeling · Standard review | Approved | None posted |
| Apr 14, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jul 17, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jun 18, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 19, 2012 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 7, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters